Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $776.57M |
| Gross Profit (TTM) | $724.04M |
| EBITDA | $-172.92M |
| Operating Margin | -23.40% |
| Return on Equity | -245.10% |
| Return on Assets | -16.30% |
| Revenue/Share (TTM) | $15.25 |
| Book Value | $1.59 |
| Price-to-Book | 121.64 |
| Price-to-Sales (TTM) | 10.91 |
| EV/Revenue | 12.93 |
| EV/EBITDA | -14.81 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 45.50% |
| Shares Outstanding | $52.38M |
| Float | $44.46M |
| % Insiders | 15.08% |
| % Institutions | 74.32% |
Volatility is currently contracting
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep pipeline of mRNA-based vaccines and oncology therapies.
The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one's quality of life, and three in four wish they had recognized symptoms sooner Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana Survey conducted by The Harris Poll and in collaboration with CaringKind NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer's Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer's disease and their family care partners.
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer's disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana.
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m.
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AXSM and any ticker you trade — then tracks every position and per-strategy win rate.
